Harrow vs Kamada
HROW and KMDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HROW and KMDA compare
Harrow grew revenue faster over the last twelve months (21.3% versus 13.2% for Kamada).
Harrow scores higher on the StockData Score (6 against 5 for Kamada), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HROW | KMDA |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | – |
| Share price | $30.12 | $8.09 |
| Change, 1 year | −21.6% | 11.1% |
| Change, 5 years | 179% | 44.5% |
| Beta (5Y) | 1.37 | 0.76 |
| Employees | 373 | 393 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.7× | – |
| P/B | 38.7× | – |
| FCF yield | −1.8% | – |
| Growth | ||
| Revenue growth (TTM) | 21.3% (better) | 13.2% |
| Revenue growth, 5Y average | 41.0% (better) | 6.3% |
| EPS growth, 5Y average | – | −1.6% |
| Profitability | ||
| Gross margin | 73.5% (better) | 40.8% |
| Operating margin | −2.0% | 14.5% (better) |
| Net margin | −9.4% | – |
| FCF margin | −6.7% | – |
| Return on equity | −74.8% | – |
| Return on invested capital | −2.1% | – |
| Financial health | ||
| Debt / equity | 10.03 | – |
| Net debt / EBITDA | – | −0.54 |
| Interest coverage | −0.3× | 26.8× (better) |
| Current ratio | 2.29 | 4.06 (better) |
| Altman Z-score | 2.07 | – |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 57.4% | 8.6% |
| Held by insiders | 14.2% | 45.3% |
| Insider net buying, 12 months | −$9.2M | −$1.7M (better) |
| Short interest, % of float | 22.1% | 0.53% |
Go deeper
- HROW stock overview
- HROW income statement
- HROW valuation and score
- KMDA stock overview
- KMDA income statement
- KMDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.